<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="monograph-family" /><meta name="keywords" content="Antifungal drugs; Fungal infections; Thrush see Candidiasis; Candidosis see Candidiasis; Candidiasis; Infections: fungal; Aspergillosis; Voriconazole; Amphotericin; Caspofungin; Itraconazole; Posaconazole; Candidiasis: oropharyngeal; Fungal infections: oral; Fluconazole; Itraconazole; Candidiasis: systemic; Echinocandin antifungals; Voriconazole; Flucytosine; Cryptococcosis; Meningitis: cryptococcal; Amphotericin; Flucytosine; Fluconazole; Histoplasmosis; Itraconazole; Amphotericin; Dermatophyte infections; Tinea infections; Onychomycosis see Fungal infections; Infections: nail, fungal; Itraconazole; Terbinafine; Griseofulvin; Pityriasis versicolor; Fluconazole; Infections: nail, fungal; Fluconazole; Itraconazole; Micafungin; Amphotericin; Caspofungin" /><meta name="IX" content="Antifungal drugs; Fungal infections; Candidiasis; Infections: fungal; Aspergillosis; Voriconazole; Amphotericin; Caspofungin; Itraconazole; Posaconazole; Candidiasis: oropharyngeal; Fungal infections: oral; Fluconazole; Itraconazole; Candidiasis: systemic; Echinocandin antifungals; Voriconazole; Flucytosine; Cryptococcosis; Meningitis: cryptococcal; Amphotericin; Flucytosine; Fluconazole; Histoplasmosis; Itraconazole; Amphotericin; Dermatophyte infections; Tinea infections; Infections: nail, fungal; Itraconazole; Terbinafine; Griseofulvin; Pityriasis versicolor; Fluconazole; Infections: nail, fungal; Fluconazole; Itraconazole; Micafungin; Amphotericin; Caspofungin" /><meta name="IXN" content="Thrush see Candidiasis; Candidosis see Candidiasis; Onychomycosis see Fungal infections" /><title>Treatment of fungal infections: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="102291.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="102291.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=102291.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="2071.htm">5 Infections</a> &gt; <a href="3968.htm">5.2 Antifungal drugs</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="3968.htm" title="Previous: 5.2 Antifungal drugs">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="208201.htm" title="Next: 5.2.1 Triazole antifungals">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_102291">Treatment of fungal infections</h1><?highlighter on?><div id="pC" class="jN"><div><p>The systemic treatment of common fungal
infections is outlined below; specialist treatment is required in
most forms of systemic or disseminated fungal infections. For local
treatment of fungal infections, <a title="" href="4532.htm#_4532">see section 7.2.2</a> (genital), <a title="BNF:sub-section: Bladder instillations and urological surgery" href="4657.htm#_4657">section 7.4.4</a> (bladder), <a title="BNF:sub-section: Antifungals" href="5410.htm#_5410">section 11.3.2</a> (eye), <a title="BNF:monograph-family: Anti-infective preparations" href="5597.htm#_5597">section 12.1.1</a> (ear), <a title="BNF:monograph-family: Oropharyngeal fungal infections" href="5702.htm#_5702">section 12.3.2</a> (oropharynx),
and <a title="BNF:sub-section: Antifungal preparations" href="6148.htm#_6148">section 13.10.2</a> (skin).</p><div class="cAZ"><h2>Aspergillosis</h2> <p class="cAX">Aspergillosis most commonly affects the respiratory
tract but in severely immunocompromised patients, invasive forms can
affect the heart, brain, and skin. <b><span>Voriconazole</span></b> (<a title="BNF:monograph: VORICONAZOLE" href="119740.htm#_119740">section 5.2.1</a>) is the treatment of choice for
aspergillosis; <b><span>liposomal amphotericin</span></b> (<a title="BNF:sub-section: Polyene antifungals" href="208203.htm#_208203">section 5.2.3</a>) is an alternative first-line
treatment when voriconazole cannot be used. <b><span>Caspofungin</span></b> (<a title="BNF:sub-section: Echinocandin antifungals" href="208205.htm#_208205">section 5.2.4</a>), <b><span>itraconazole</span></b> (<a title="BNF:monograph: ITRACONAZOLE" href="3981.htm#_3981">section 5.2.1</a>), or <b><span>posaconazole</span></b> (<a title="BNF:monograph: POSACONAZOLE" href="129707.htm#_129707">section 5.2.1</a>) can be used in patients who
are refractory to, or intolerant of voriconazole and liposomal amphotericin.
Itraconazole is also used for the treatment of chronic pulmonary aspergillosis
or as an adjunct in the treatment of allergic bronchopulmonary aspergillosis
[unlicensed indication].</p></div><div class="cAZ" id="_102291.2"><h2>Candidiasis</h2> <p class="cAX">Many superficial candidal infections
including infections of the skin (<a title="target-block: candidiasis" href="6148.htm#_6148.5">section 13.10.2</a>) are treated locally; widespread
or intractable infection requires systemic antifungal treatment. Vaginal
candidiasis (<a title="" href="4532.htm#_4532">section 7.2.2</a>) may be
treated with locally acting antifungals or with <b>fluconazole</b> (<a title="BNF:monograph: FLUCONAZOLE" href="3974.htm#_3974">section 5.2.1</a>) given by mouth; for resistant
organisms, <b>itraconazole</b> (<a title="BNF:monograph: ITRACONAZOLE" href="3981.htm#_3981">section 5.2.1</a>) can be given by mouth.</p> <p class="cAX"><i>Oropharyngeal candidiasis</i> generally responds to topical therapy (<a title="" href="5701.htm#_5701">section 12.3.2</a>); fluconazole
is given by mouth for unresponsive infections; it is effective and is reliably absorbed. Itraconazole may be used for infections
that do not respond to fluconazole. Topical therapy may not be adequate
in immunocompromised patients and an oral triazole antifungal is preferred.</p><p>For <i>invasive or disseminated candidiasis</i>, an <b>echinocandin</b> (<a title="BNF:sub-section: Echinocandin antifungals" href="208205.htm#_208205">section 5.2.4</a>) can
be used. <b>Fluconazole</b> (<a title="BNF:monograph: FLUCONAZOLE" href="3974.htm#_3974">section 5.2.1</a>) is an alternative for <span class="cAC">Candida albicans</span> infection in clinically stable patients
who have not received an azole antifungal recently. <b><span>Amphotericin</span></b> (<a title="BNF:sub-section: Polyene antifungals" href="208203.htm#_208203">section 5.2.3</a>) is an alternative when an echinocandin
or fluconazole cannot be used, however, amphotericin should be considered
for the initial treatment of CNS candidiasis. <b>Voriconazole</b> (<a title="BNF:monograph: VORICONAZOLE" href="119740.htm#_119740">section 5.2.1</a>) can be used for infections caused
by fluconazole-resistant <span class="cAC">Candida</span> spp. when oral
therapy is required, or in patients intolerant of amphotericin or
an echinocandin. In refractory cases, <b>flucytosine</b> (<a title="BNF:sub-section: Other antifungals" href="208206.htm#_208206">section 5.2.5</a>) can be used with intravenous
amphotericin.</p></div><div id="_102291.10"><div class="cAZ"><h2>Cryptococcosis</h2> <p class="cAX">Cryptococcosis is uncommon but infection in the immunocompromised,
especially in HIV-positive patients, can be life-threatening; cryptococcal meningitis is the
most common form of fungal meningitis. The treatment of choice in
cryptococcal meningitis is <b>amphotericin</b> (<a title="BNF:monograph: AMPHOTERICIN" href="3969.htm#_3969">section 5.2.3</a>) by intravenous infusion and <b>flucytosine</b> (<a title="BNF:monograph: FLUCYTOSINE" href="3976.htm#_3976">section 5.2.5</a>) by intravenous infusion for
2 weeks, followed by <b>fluconazole</b> (<a title="BNF:monograph: FLUCONAZOLE" href="3974.htm#_3974">section 5.2.1</a>) by mouth for 8 weeks or until
cultures are negative. In cryptococcosis, <b>fluconazole</b> is sometimes given alone as an alternative
in HIV-positive patients with mild, localised infections or in those
who cannot tolerate amphotericin. Following successful treatment,
fluconazole can be used for prophylaxis against relapse until immunity
recovers.</p></div></div><div class="cAZ"><h2>Histoplasmosis</h2> <p class="cAX">Histoplasmosis is rare in temperate climates; it can
be life-threatening, particularly in HIV-infected persons. <b>Itraconazole</b> (<a title="BNF:monograph: ITRACONAZOLE" href="3981.htm#_3981">section 5.2.1</a>) can be used for the treatment
of immunocompetent patients with indolent non-meningeal infection,
including chronic pulmonary histoplasmosis. <b>Amphotericin</b> (<a title="BNF:sub-section: Polyene antifungals" href="208203.htm#_208203">section 5.2.3</a>) by intravenous infusion is preferred
in patients with fulminant or severe infections. Following successful
treatment, <span>itraconazole</span> can be used for prophylaxis
against relapse until immunity recovers.</p></div><div id="_200994"><div class="cAZ"><h2>Skin and nail infections</h2> <p class="cAX">Mild localised fungal
infections of the skin (including tinea corporis,
tinea cruris, and tinea pedis) respond to topical therapy (<a title="sub-section: Antifungal preparations" href="6148.htm#_6148">section 13.10.2</a>). Systemic therapy is appropriate
if topical therapy fails, if many areas are affected, or if the site
of infection is difficult to treat such as in infections of the nails
(onychomycosis) and of the scalp (tinea capitis). Oral <a title="BNF:sub-section: Imidazole antifungals" href="208204.htm#_208204">imidazole</a> or <a title="BNF:sub-section: Triazole antifungals" href="208201.htm#_208201">triazole antifungals</a> (particularly <a title="BNF:monograph: ITRACONAZOLE" href="3981.htm#_3981"><b><span>itraconazole</span></b></a>) and <a title="BNF:monograph: TERBINAFINE" href="3990.htm#_3990"><b><span>terbinafine</span></b></a> are used more frequently than griseofulvin because they have a broader
spectrum of activity and require a shorter duration of treatment.</p><p><i>Tinea capitis</i> is treated systemically; additional
topical application of an antifungal (<a title="sub-section: Antifungal preparations" href="6148.htm#_6148">section 13.10.2</a>) may reduce transmission. <b><span>Griseofulvin</span></b> (<a title="BNF:monograph: GRISEOFULVIN" href="3978.htm#_3978">section 5.2.5</a>) is used for tinea capitis in
adults and children; it is effective against infections caused by <span class="cAC">Trichophyton tonsurans</span> and <span class="cAC">Microsporum</span> spp. <span><b>Terbinafine</b></span> (<a title="BNF:monograph: TERBINAFINE" href="3990.htm#_3990">section 5.2.5</a>) is used for tinea capitis caused
by <span class="cAC">T. tonsurans</span> [unlicensed indication]. The
role of terbinafine in the management of <span class="cAC">Microsporum</span> infections is uncertain.</p><p><i>Pityriasis versicolor</i> (<a title="target-block: Pityriasis versicolor" href="6148.htm#_6148.3">section 13.10.2</a>) may be treated with <b>itraconazole</b> (<a title="BNF:monograph: ITRACONAZOLE" href="3981.htm#_3981">section 5.2.1</a>) by mouth if topical therapy
is ineffective; <b>fluconazole</b> (<a title="BNF:monograph: FLUCONAZOLE" href="3974.htm#_3974">section 5.2.1</a>) by mouth is an alternative.
Oral <b>terbinafine </b>is <b>not </b>effective
for pityriasis versicolor.</p><p>Antifungal treatment may not be necessary in asymptomatic patients
with tinea infection of the nails. If treatment is necessary, a systemic
antifungal is more effective than topical therapy. <b>Terbinafine</b> (<a title="BNF:monograph: TERBINAFINE" href="3990.htm#_3990">section 5.2.5</a>) and <b>itraconazole</b> (<a title="BNF:monograph: ITRACONAZOLE" href="3981.htm#_3981">section 5.2.1</a>) have largely replaced griseofulvin
for the systemic treatment of <i>onychomycosis</i>, particularly of
the toenail; terbinafine is considered to be the drug of choice. Itraconazole
can be administered as intermittent ‘pulse’ therapy. For the role
of topical antifungals in the treatment of onychomycosis, see <a title="sub-section: Antifungal preparations" href="6148.htm#_201036">section 13.10.2</a>.</p></div></div><div id="_120013"><div class="cAZ"><h2>Immunocompromised patients</h2> <p class="cAX">Immunocompromised patients
are at particular risk of fungal infections and may receive antifungal
drugs prophylactically; oral triazole antifungals are the drugs of
choice for prophylaxis. <b>Fluconazole</b> (<a title="BNF:monograph: FLUCONAZOLE" href="3974.htm#_3974">section 5.2.1</a>) is more reliably absorbed than <b>itraconazole</b> (<a title="BNF:monograph: ITRACONAZOLE" href="3981.htm#_3981">section 5.2.1</a>), but fluconazole is not effective
against <span class="cAC">Aspergillus</span> spp. Itraconazole is preferred
in patients at risk of invasive aspergillosis. <b>Posaconazole</b> (<a title="BNF:monograph: POSACONAZOLE" href="129707.htm#_129707">section 5.2.1</a>) can be used for prophylaxis
in patients who are undergoing haematopoietic stem cell transplantation
or receiving chemotherapy for acute myeloid leukaemia and myelodysplastic
syndrome, if they are intolerant of fluconazole or itraconazole. <b>Micafungin</b> (<a title="BNF:monograph: MICAFUNGIN" href="201531.htm#_201531">section 5.2.4</a>) can be used for prophylaxis
of candidiasis in patients undergoing haematopoietic stem cell transplantation
when fluconazole, itraconazole or posaconazole cannot be used.</p><p><span><b>Amphotericin</b></span> (<a title="BNF:monograph: AMPHOTERICIN" href="3969.htm#_3969">section 5.2.3</a>) by intravenous infusion or <b>caspofungin</b> (<a title="BNF:monograph: CASPOFUNGIN" href="119732.htm#_119732">section 5.2.4</a>) is used for the empirical <i>treatment</i> of serious fungal infections; caspofungin is not
effective against fungal infections of the CNS.</p></div></div></div></div><?highlighter on?><?highlighter off?><div id="pE">◄ <a accesskey="[" href="3968.htm">Previous: 5.2 Antifungal drugs</a> | <a class="top" href="102291.htm#">Top</a> | <a accesskey="]" href="208201.htm">Next: 5.2.1 Triazole antifungals</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>